Article
Endocrinology & Metabolism
Cristian Iorga, Cristina Raluca Iorga, Iuliana Andreiana, Iustinian Bengulescu, Traian Constantin, Victor Strambu
Summary: After analyzing the obtained results, it was concluded that total parathyroidectomy is the preferred intervention for patients with secondary hyperparathyroidism when pharmacotherapy fails, in order to prevent disease recurrence and correct metabolic parameters.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Urology & Nephrology
Massimo Morosetti, Ljiljana Jankovic, Laura Zappala, Elena Agafonova, Iryna Pryshlyak
Summary: This study evaluated the long-term use of etelcalcetide for the treatment of secondary hyperparathyroidism in patients with end-stage renal failure. The results demonstrate that etelcalcetide is effective in maintaining the desired outcomes over the long term.
INTERNATIONAL UROLOGY AND NEPHROLOGY
(2023)
Review
Endocrinology & Metabolism
Takahisa Hiramitsu, Yuki Hasegawa, Kenta Futamura, Manabu Okada, Norihiko Goto, Shunji Narumi, Yoshihiko Watarai, Yoshihiro Tominaga, Toshihiro Ichimori
Summary: Secondary hyperparathyroidism is a major problem for chronic kidney disease patients, causing various complications. While treatment for SHPT has changed with the advent of calcimimetics, parathyroidectomy remains an essential treatment option.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Surgery
Willemijn Van der Plas, Schelto Kruijff, Stan B. Sidhu, Leigh W. Delbridge, Mark S. Sywak, Anton F. Engelsman
Summary: This study compared the outcomes of limited, subtotal, and total parathyroidectomy for end-stage renal disease-related hyperparathyroidism, and found that subtotal parathyroidectomy is the optimal strategy. It suggests a shift towards a less aggressive and patient-tailored approach in parathyroid surgery in the changing landscape of kidney transplantation availability and improved dialysis regimens.
Article
Pharmacology & Pharmacy
Yiping Liu, Qian Yang, Guangyong Chen, Tianbiao Zhou
Summary: Calcimimetic agents are effective in the treatment of secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) patients, reducing PTH, Ca, P, and calcium-phosphorus product levels without increasing serious adverse events.
CURRENT PHARMACEUTICAL DESIGN
(2022)
Article
Cardiac & Cardiovascular Systems
Huayan Xu, Wanlin Peng, Zhigang Yang, Yi Zhang, Chunchao Xia, Zhenlin Li, Rong Xu, Yingkun Guo
Summary: The study found that elevated iPTH levels were associated with myocardial damage in ESRD patients undergoing maintenance hemodialysis, and were an independent risk factor for myocardial damage.
JOURNAL OF CARDIOVASCULAR MAGNETIC RESONANCE
(2021)
Article
Urology & Nephrology
Daijo Inaguma, Fumihiko Koiwa, Masanori Tokumoto, Masafumi Fukagawa, Shinji Yoneda, Hisami Yasuzawa, Kenji Asano, Keiko Hagita, Yosuke Inagaki, Daisuke Honda, Tadao Akizawa
Summary: The long-term efficacy and safety of upacicalcet treatment in haemodialysis patients with secondary hyperparathyroidism (SHPT) were evaluated. The results showed that doses of 25-300 μg per week for 52 weeks were highly effective and well-tolerated, with minor safety concerns.
CLINICAL KIDNEY JOURNAL
(2023)
Review
Pharmacology & Pharmacy
Hsiao-Tien Chen, Kuo-Chuan Hung, Chin-Wei Hsu, Jui-Yi Chen, Chien-Cheng Liu, I-Wen Chen, Cheuk-Kwan Sun
Summary: This study analyzed randomized controlled trials comparing cuttlebone with conventional interventions and found that cuttlebone can more effectively treat hyperphosphatemia in patients with end-stage renal disease, with fewer side effects.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Surgery
Catherine McManus, Aaron Oh, James A. Lee, Chin Hur, Jennifer H. Kuo
Summary: Combining cinacalcet with PTX before kidney transplant is the most cost-effective strategy for treating tertiary hyperparathyroidism in patients with end-stage renal disease.
Article
Multidisciplinary Sciences
Naila Noureen, Nousheen Zaidi
Summary: We conducted a meta-analysis to determine the association between HLA alleles and ESRD. The results showed no significant association between HLA-B*50, HLA-DQA1*3, B*40, DRB1*12, DRB1*13, and DQA1*6 alleles and ESRD. Further studies with larger sample sizes and adjustments for confounders are needed to confirm these conclusions.
Article
Biochemistry & Molecular Biology
Ziad M. El-Zaatari, Luan D. Truong
Summary: Renal cell carcinoma (RCC) occurring in the setting of end-stage renal disease (ESRD) shows unique clinicopathological characteristics, with acquired cystic kidney disease-associated renal cell carcinoma (ACKD-RCC) and clear-cell papillary renal cell carcinoma (ccpRCC) being the most frequent types. Other types of RCC also occur in ESRD, albeit with different frequencies from the non-ESRD general population. While the histological features of RCC do not vary in the setting of ESRD vs. non-ESRD, other findings, such as multifocality and multiple tumor types, are more frequent in ESRD. Studies have generated novel and important knowledge of the etiology, epidemiology, diagnosis, treatment, immunophenotype, and molecular characteristics of ESRD-associated RCC.
Review
Public, Environmental & Occupational Health
Ruochan Chen, Yinghui Xiong, Yanyang Zeng, Xiaolei Wang, Yinzong Xiao, Yixiang Zheng
Summary: This study aims to compare the efficacy and safety of different direct-acting antiviral regimens (DAAs) in end-stage renal disease (ESRD) patients with hepatitis C virus (HCV) infection, providing evidence for clinical decision-making.
FRONTIERS IN PUBLIC HEALTH
(2023)
Review
Medicine, General & Internal
Xu Jing, Wen Zhuyuan, Chen Aijun, Xiong Jianxia, Huang Kun, Wang Ping
Summary: Previous studies have shown that patients with psoriasis are at higher risk of developing CKD and ESRD compared with the general population, but data on the differences in occurrence between psoriasis and non-psoriatic controls are limited and inconsistent. This study conducted a meta-analysis of cohort studies to compare the probability of suffering CKD and ESRD in patients with or without psoriasis.
FRONTIERS IN MEDICINE
(2023)
Article
Dermatology
Shanshan Yan, Dongfang Yao, Ya Wang, Jian Zhang
Summary: This study aimed to assess the risk factors for foot ulcers in dialysis patients with end-stage renal disease (ESRD) and provide evidence-based guidance for prevention and treatment. A systematic search was conducted, and six articles comprising 1620 patients were included for analysis. The meta-analysis revealed that male sex, hypertension, peripheral artery disease, type 1 diabetes mellitus, and type 2 diabetes mellitus were risk factors for foot ulcers in dialysis patients with ESRD, while female sex was a protective factor.
INTERNATIONAL WOUND JOURNAL
(2023)
Article
Cell Biology
Zaipul I. Md Dom, Eiichiro Satake, Jan Skupien, Bozena Krolewski, Kristina O'Neil, Jill A. Willency, Simon T. Dillon, Jonathan M. Wilson, Hiroki Kobayashi, Katsuhito Ihara, Towia A. Libermann, Marlon Pragnell, Kevin L. Duffin, Andrzej S. Krolewski
Summary: This study identified three elevated plasma proteins associated with protection against progressive renal decline and progression to endstage renal disease in individuals with diabetes. These protective proteins may serve as biomarkers for stratifying diabetic individuals by their risk of developing ESRD, and could be explored as potential therapeutics to delay or prevent ESRD onset.
SCIENCE TRANSLATIONAL MEDICINE
(2021)